Ruxolitinib 1.5% cream can be used for the short-term and noncontinuous treatment of mild to moderate atopic dermatitis in immunocompetent patients 12 years of age and older whose disease is not adequately controlled with other topical prescription therapies or when those therapies are not advisable.